Directorate Appointment

Surgical Innovations Group PLC
02 October 2007




Press Release                                                    2 October 2007



                        Surgical Innovations Group plc
                             ('SI' or 'the Group')



               Appointment of Non-Executive Clinical Director

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of
innovative surgical devices, announces that Professor Michael John McMahon, a
global pioneer in minimally invasive surgery, has been appointed to the Group
Board as Non-Executive Clinical Director with immediate effect.

One of Professor McMahon's key roles will be to chair Surgical Innovations' new
Clinical Advisory Board which has been established to further enhance the
Group's links with leading minimally invasive ('keyhole' or 'laparoscopic')
surgeons around the world.

Professor McMahon holds a Chair in Surgery at the University of Leeds and is
Consultant Surgeon at the Leeds Teaching Hospitals NHS Trust.  He is currently
President of the Association of Laparoscopic Surgeons of Great Britain and
Ireland (ALS), and was recently a Royal College of Surgeons' tutor in minimally
invasive surgery.  Past roles include President of the Pancreatic Society of
Great Britain and Ireland and Chairman of the Education Committee of the
European Association of Endoscopic Surgery.

Notably, Professor McMahon developed a new technique for the laparoscopic
removal of the gall bladder and he was the first surgeon in the UK to carry out
a laparoscopic gastric by-pass.  He introduced the operation of the sleeve
gastrectomy as a stand-alone procedure for the treatment of obesity and
established the Leeds Institute for Minimally Invasive Therapy (LIMIT).

Commenting on the appointment, Chairman Doug Liversidge, said: 'Professor
McMahon's new role and the establishment of the Clinical Advisory Board will
considerably enhance our international relationships with leading surgeons.
This two way outreach not only complements the links already forged by our sales
team and distributors, but will also speed up our product development programme
for resposableTM instruments as we pool fresh ideas from hospitals around the
world.

'Professor McMahon's in-depth experience of the operating theatre and his
contacts within the field of minimally invasive surgery are second to none,
whilst his involvement in the teaching of laparoscopic techniques is vital in
encouraging the ongoing uptake of innovative surgical devices.  It is with great
pleasure that we welcome a true pioneer onto the Surgical Innovations Group
Board where, as co-founder of Surgical Innovations Limited in 1992, he invented
our Endoflex device which is still regarded as one of the best retractors
available today.'


Regulatory Information

Professor McMahon, aged 65, was previously a director of Surgical Innovations
Limited between February 1992 and June 2007.  There are no further disclosures
required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

Professor McMahon holds 9,801,934 Ordinary Shares in the Company, representing
approximately 2.62 per cent of the issued share capital.  In addition he holds
share options as follows:


No of shares under option     Exercise price:                   Exercise period:
                1,000,000                  3p     November 2003 to November 2010
                1,000,000                  2p            April 2004 to June 2011



                                    - Ends -


For further information:
Surgical Innovations Group plc
Graham Bowland, Finance Director                      Tel: [phone]
[e-mail]                                www.sigroupplc.com

Hanson Westhouse Limited
Tim Feather / Matthew Johnson                         Tel: [phone]
[e-mail]                         www.hansonwesthouse.com

Media enquiries:
Abchurch
Gareth Mead / Emma Johnson                            Tel: [phone]
[e-mail]                           www.abchurch-group.com



Notes to Editors:

Surgical Innovations Group plc specialises in the design and manufacture of
innovative devices for use in minimally invasive surgery and industrial markets.
The Group employs over 40 people and is headquartered in Leeds.

The Group's subsidiaries Surgical Innovations Limited and Haemocell Limited are
focused on strong international growth in two specialist areas namely minimally
invasive surgery, where products are used in 'keyhole' surgery which is more
accurately known as laparoscopic surgery, and products for autologous blood
transfusion whereby a patient's own blood is recycled.

The Group's subsidiary company Core Precision Limited utilises Surgical
Innovations' core medical device design expertise and technology in innovative
engineering applications.

For more information, see www.sigroupplc.com



                      This information is provided by RNS
            The company news service from the London Stock Exchange